In Vivo CRO Market Size is Poised to be Valued at USD 11.83 Billion by 2035; Growth is Driven by the Increasing Preference from Different Companies Globally | SNS Insider
Austin, May 20, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The In Vivo CRO Market was valued at USD 5.48 Billion in 2025 and is expected to reach USD 11.83 Billion by 2035, growing at a CAGR of 8.0% over 2026-2035.
The growth of the market is driven by the industry-wide shift within the pharmaceutical industry from in-house preclinical research to outsourcing such activities, since it makes better economic sense for companies to outsource their research needs to specialized CROs that can do so more effectively and at a lower fixed cost than the companies themselves.
Get a Sample Report of In Vivo CRO Market Growth Strategy @ https://www.snsinsider.com/sample-request/5868
The U.S. In Vivo CRO Market was valued at USD 2.69 Billion in 2025 and is expected to reach USD 5.80 Billion by 2035, growing at a CAGR of 8.0% from 2026-2035.
The market growth is attributed to the robust research and development environment for pharmaceuticals and biotech in the United States. The U.S. biopharmaceutical industry, which boasts the largest number of global headquarters, drug pipelines, and approvals, is the largest procurer of in vivo CRO services.
The Europe In Vivo CRO Market is estimated to be USD 1.62 Billion in 2025 and is projected to reach USD 3.38 Billion by 2035, growing at a CAGR of 7.63% during 2026–2035.
Europe has an important market share in the In Vivo CRO market, with the United Kingdom, Germany, France, and Switzerland representing the major national markets. The European CRO business caters to pharmaceutical companies operating both in Europe and America that wish to diversify geographically.
Pharmaceutical Pipeline Expansion and Preclinical Outsourcing Adoption to Augment Market Growth Globally
The basic economic model of the in vivo CRO industry revolves around the fact that pharmaceutical companies have realized it is more cost-effective for them to contract the process of in vivo testing from external specialists rather than building the necessary facilities to conduct such tests on their own. Maintaining an in vivo laboratory in accordance with the GLP standards involves having an animal care staff, specialized facilities, and ongoing documentation, which incur fixed costs irrespective of variations in demand. This makes the business model of the CRO much more efficient compared to that of a pharmaceutical company.
Segmentation Analysis:
By Model Type
Rodent-based segment dominated with 80% share in 2025 due to its cost-effectiveness, well-established biological relevance, and widespread regulatory acceptance in preclinical research. Non-rodent segment is gaining traction as demand rises for higher translational accuracy and regulatory validation in advanced therapeutic areas.
By Modality
Small molecules dominated the In Vivo CRO Market in 2025, supported by their long-standing presence in drug discovery pipelines and cost efficiency globally. The cell and gene therapy is emerging as the fastest-growing modality, driven by increasing investment in precision medicine, regenerative therapies, and targeted treatment approaches for previously incurable diseases.
By Indication
Oncology dominated the In Vivo CRO Market in 2025 due to the high global cancer burden and continuous pipeline expansion globally. CNS disorders and autoimmune diseases are witnessing rapid growth driven by rising prevalence of neurological conditions such as Alzheimer’s, Parkinson’s, and depression globally.
By GLP Type
GLP toxicology dominated the In Vivo CRO Market in 2025, as regulatory-compliant safety studies are mandatory for drug approval processes across global regulatory agencies such as the FDA and EMA. The non-GLP studies are growing steadily, driven by increased early-stage drug discovery activity and the expansion of preclinical pipelines in biotech and academic research.
For an In-Depth Strategic Briefing with Our Research Team, Connect Now @ https://www.snsinsider.com/request-analyst/5868
Regional Insights:
North America represented nearly 49% share of the global In Vivo CRO Market in 2025 owing to its leading position in terms of investment in pharmaceutical R&D, having the largest number of drug development firms ranging from early-stage biotech firms to global pharmaceutical firms, and featuring the most prominent CROs like Charles River Laboratories and Labcorp Drug Development.
The Asia Pacific region is the fastest growing market for In Vivo CROs. India is expected to have the highest country-level compound annual growth rate (CAGR) in the region during the forecast period. The presence of qualified scientific manpower, low operating costs of up to 40-60% compared to the United States, better regulatory framework, and government initiatives, such as 'Pharma Vision' make India an attractive destination for outsourcing.
Major Players Analysis Listed in the In Vivo CRO Market Report:
Recent Developments:
Purchase Single User PDF of In Vivo CRO Market Report @ https://www.snsinsider.com/checkout/5868
Exclusive Sections of the Report (The USPs):
In Vivo CRO Market Report Scope
Accelerated In Vivo CRO Market Demand: Find Comprehensive Insights and Trends in Our Full Report @ https://www.snsinsider.com/reports/in-vivo-cro-market-5868
Other Trending Related Report:
Electronic Clinical Outcome Assessment Solutions Market
Clinical Trial Equipment & Ancillary Solutions Market
Cell And Gene Therapy Clinical Trials Market
Pediatric Clinical Trials Market
In Silico Clinical Trials Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.